Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28533470 | 0.78 | GABRA1 (0.41) | GAAALOX15KDM4ELMNACYP1A2 | |
| SCHEMBL9614876 | 0.75 | GABRA1 (0.39) | GAAALOX15KDM4ELMNACYP1A2 | |
| SCHEMBL18668719 | 0.75 | KMT2A (0.40) | GAAALOX15KDM4ELMNACYP1A2 | |
| SCHEMBL251314 | 0.73 | PTGDR2 (0.40) | GAAALOX15KDM4ELMNACYP1A2 | |
| SCHEMBL14159147 | 0.72 | KDM4E (0.39) | GAAALOX15KDM4ELMNACYP1A2 | |
| SCHEMBL11422337 | 0.71 | GABRA1 (0.40) | GAAALOX15KDM4ELMNACYP1A2 | |
| SCHEMBL8609210 | 0.71 | KDM4E (0.39) | GAAALOX15KDM4ELMNACYP1A2 | |
| 2-Allylphenol SCHEMBL10426340 | 0.70 | GABRA1 (0.42) | GAAALOX15KDM4ELMNACYP1A2 | |
| SCHEMBL21885665 | 0.69 | BRD4 (0.51) | LMNACYP3A4CYP2D6CYP2C9HTT | |
| SCHEMBL30436948 | 0.69 | BRD4 (0.51) | LMNACYP3A4CYP2D6CYP2C9HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130101615-A1 | METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS | GREENSTEIN ROBERT J (US) | 2013-04-25 | — | — | US | disclosed |
| US-20100093829-A1 | METHODS FOR PREVENTING, POSTPONING OR IMPROVING THE OUTCOME OF SPINAL DEVICE AND FUSION PROCEDURES | BIOASSETS DEVELOPMENT CORPORATION | 2010-04-15 | — | — | US | disclosed |
| US-20100047235-A1 | NOVEL REGIMENS FOR TREATING DISEASES AND DISORDERS | BIOASSETS DEVELOPMENT CORPORATION | 2010-02-25 | — | — | US | disclosed |
| US-20100040609-A1 | METHODS FOR PREVENTING, POSTPONING OR IMPROVING THE OUTCOME OF INVASIVE SPINAL PROCEDURES | BIOASSETS DEVELOPMENT CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20090054380-A1 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection | GREENSTEIN ROBERT J | 2009-02-26 | — | — | US | disclosed |
| US-7479499-B2 | Methods of using thalidomide in combination with irinotecan | CELGENE CORPORATION (US) | 2009-01-20 | — | — | US | disclosed |
| US-20090012048-A1 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection | GREENSTEIN ROBERT J | 2009-01-08 | — | — | US | disclosed |
| US-7435726-B2 | Compositions and methods for the treatment of cancer | CELGENE CORPORATION (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080019970-A1 | METHODS FOR PREVENTING, POSTPONING OR IMPROVING THE OUTCOME OF SPINAL DEVICE AND FUSION PROCEDURES | BIOASSETS DEVELOPMENT CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080019975-A1 | Novel Regimens for Treating Diseases and Disorders | BIOASSETS DEVELOPMENT CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-6914067-B2 | Compositions and methods for the treatment of colorectal cancer | CELGENE CORPORATION (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1343500-A2 | COMPOSITIONS COMPRISING TEMOZOLOMIDE AND THALIDOMIDE AND METHODS FOR THE TREATMENT OF CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1307197-A2 | COMPOSITIONS FOR THE TREATMENT OF CANCER COMPRISING A TOPOISOMERASE INHIBITOR AND THALIDOMIDE | CELGENE CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1286671-A2 | COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER COMPRISING THALIDOMIDE AND IRINOTECAN | CELGENE CORPORATION (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020128228-A1 | Using temozolomide and thalidomide; side effect reduction; improve the efficacy of either drug when used alone against cancer or to improve the tolerability of either drug | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2002-09-12 | — | — | US | disclosed |
| WO-2002043720-A2 | COMPOSITIONS COMPRISING TEMOZOLOMIDE AND THALIDOMIDE AND METHODS FOR THE TREATMENT OF CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-06 | — | — | WO | disclosed |
| US-20020035090-A1 | Compositions and methods for the treatment of cancer | CELGENE CORPORATION | 2002-03-21 | — | — | US | disclosed |
| US-20020035091-A1 | Compositions and methods for the treatment of colorectal cancer | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2002-03-21 | — | — | US | disclosed |
| WO-2001087306-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF COLORECTAL CANCER | CELGENE CORP. (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087307-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELGENE CORP. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101615-A1 | METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS | HLA-DRB1, CD14, HLA-C | GAA 478/4885ALOX15 766/4885KDM4E 4773/4885 |
| US-20090054380-A1 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection | MAPT, MAP7, MAPK1 | GAA 394/4885ALOX15 2807/4885KDM4E 4101/4885 |
| US-20090012048-A1 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection | MAPT, MAP7, MAPK1 | GAA 394/4885ALOX15 2807/4885KDM4E 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.